http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 22 Oct 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Third+Quarter+2026+Financial+Results+on+November+5%2C+2026/27219371.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4804089-1&amp;h=2415780583&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended <chron>September 30, 2026</chron> on <chron>Thursday, November 5, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> http://www.streetinsider.com/Press+Releases/Cryoport+to+Report+Third+Quarter+2026+Financial+Results+on+November+5%2C+2026/27219371.html Thu, 22 Oct 2026 08:00:00 -0400 CYRX http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Third+Quarter+2026+Financial+Results+on+November+5%2C+2026/27219371.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4804089-1&amp;h=2415780583&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport, Inc.</span></a> (Nasdaq: CYRX) ("<span value="NASDAQ-SMALL:CYRX" idsrc="xmltag.org" >Cryoport</span>" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended <chron>September 30, 2026</chron> on <chron>Thursday, November 5, 2026</chron> after <location value="LC/us" idsrc="xmltag.org" >U.S</location>. markets close.</p> http://www.streetinsider.com/PRNewswire/Cryoport+to+Report+Third+Quarter+2026+Financial+Results+on+November+5%2C+2026/27219371.html Thu, 22 Oct 2026 08:00:00 -0400 CYRX http://www.streetinsider.com/Analyst+PT+Change/CryoPort+%28CYRX%29+PT+Raised+to+%2426+at+BTIG/27176016.html <p>BTIG analyst David Larsen raised the price target on CryoPort (NASDAQ: CYRX) to $26.00 (from $25.00) while maintaining a Buy rating.</p><p>The analyst comments "We recently brought Robert Stefanovich, CFO, and Tom Heinzen, Head of Corporate Development and IR, on the road to meet with investors in NYC. We also hosted a group site-visit to the CYRX bio-logistics and bio-services facility in Morris Plains, NJ. The overall tone of the meetings and field trip was favorable, we continue to be positive on the stock, and we increase our PT to $26. While CYRX will be opening new facilities or services in http://www.streetinsider.com/Analyst+PT+Change/CryoPort+%28CYRX%29+PT+Raised+to+%2426+at+BTIG/27176016.html Tue, 13 Oct 2026 05:07:29 -0400 CYRX http://www.streetinsider.com/Analyst+Comments/CryoPort+%28CYRX%29+PT+Raised+to+%2426+at+BTIG/27176016.html <p>BTIG analyst David Larsen raised the price target on CryoPort (NASDAQ: CYRX) to $26.00 (from $25.00) while maintaining a Buy rating.</p><p>The analyst comments "We recently brought Robert Stefanovich, CFO, and Tom Heinzen, Head of Corporate Development and IR, on the road to meet with investors in NYC. We also hosted a group site-visit to the CYRX bio-logistics and bio-services facility in Morris Plains, NJ. The overall tone of the meetings and field trip was favorable, we continue to be positive on the stock, and we increase our PT to $26. While CYRX will be opening new facilities or services in http://www.streetinsider.com/Analyst+Comments/CryoPort+%28CYRX%29+PT+Raised+to+%2426+at+BTIG/27176016.html Tue, 13 Oct 2026 05:07:29 -0400 CYRX http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+PT+Change/CryoPort+%28CYRX%29+PT+Raised+to+%2419+at+Guggenheim/27132280.html Guggenheim analyst Subbu Nambi raised the price target on CryoPort (NASDAQ: CYRX) to $19.00 (from $16.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CryoPort+%28CYRX%29+PT+Raised+to+%2419+at+Guggenheim/27132280.html Thu, 01 Oct 2026 08:47:55 -0400 CYRX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html si-local-file:///var/storage/secattach/20260814/26929582.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html Fri, 14 Aug 2026 15:35:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html si-local-file:///var/storage/secattach/20260814/26929582.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+CADIAN+CAPITAL+MANAGEMENT%2C+LP/26929582.html Fri, 14 Aug 2026 15:35:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html si-local-file:///var/storage/secattach/20260813/26922606.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html Thu, 13 Aug 2026 17:06:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html si-local-file:///var/storage/secattach/20260813/26922606.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26922606.html Thu, 13 Aug 2026 17:06:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html si-local-file:///var/storage/secattach/20260811/26907450.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html Tue, 11 Aug 2026 18:49:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html si-local-file:///var/storage/secattach/20260811/26907450.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cryoport%2C+Inc.++++++++++++For%3A+Aug+11++Filed+by%3A+SHELTON+JERRELL/26907450.html Tue, 11 Aug 2026 18:49:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html si-local-file:///var/storage/secattach/20260811/26906371.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html Tue, 11 Aug 2026 16:31:00 -0400 CYRX O.01522978 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html si-local-file:///var/storage/secattach/20260811/26906371.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cryoport%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+SHELTON+JERRELL/26906371.html Tue, 11 Aug 2026 16:31:00 -0400 CYRX O.01522978 http://www.streetinsider.com/Earnings/Cryoport+%28CYRX%29+Misses+Q2+EPS+by+1c/26885783.html <p>Cryoport (NASDAQ: CYRX) reported Q2 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $48.97 million versus the consensus estimate of $48.21 million.</p><p>For earnings history and earnings-related data on Cryoport (CYRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CYRX">click here</a>.</p> http://www.streetinsider.com/Earnings/Cryoport+%28CYRX%29+Misses+Q2+EPS+by+1c/26885783.html Thu, 06 Aug 2026 17:50:18 -0400 CYRX